$NCEL News
Last published 2d ago
- 2d agoNCELNewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to MarketGlobeNewswireZURICH, Nov. 09, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced that it has entered into
- 2d agoNCELNewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to MarketGlobeNewswireThe financing led by international healthcare investors, alongside The Crushing T1 Foundation, reinforces confidence in NewcelX’s strategy and long-term potential
- 1w agoNCELNewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone PaymentsGlobeNewswireTransaction provides $500,000 upfront of which $30,000 is in cash and the remainder in shares, representing a 9.4% equity stake in REA Holdings, alongside potential worldwide royalties of up to 8% Strategic divestiture
- 3mo agoNCELNewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium PricingGlobeNewswireZURICH, Switzerland, July 31, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for type 1 diabetes, today announced that it has
- 3mo agoNCELNewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP PortfolioGlobeNewswireZURICH, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian
- 4mo agoNCELNewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory BoardGlobeNewswireThe appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials Dr. Ricordi to support advancement of
- 4mo agoSANAELDNNCELVRTXThe Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho TherapyPR NewswireUSA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the...
- 4mo agoNCELELDNNewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 DiabetesGlobeNewswireZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion of
- 4mo agoNCELNewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology PlatformGlobeNewswireStudy published in Stem Cell Reports demonstrates that AstroRx® - a therapy derived from NewcelX's platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including
- 5mo agoELDNNCELNewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 DiabetesGlobeNewswirePre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a
- 6mo agoELDNNCELNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026GlobeNewswireNewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver
- 6mo agoELDNNCELNewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceGlobeNewswireZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced
- 7mo agoNCELNewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium PricingGlobeNewswireFinancing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage
- 8mo agoNCELELDNNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesPR NewswireNewcelX Ltd. ("NewcelX") (Nasdaq: NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a...
- 9mo agoNCELNewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization StrategyPR NewswireNewcelX Ltd. ("NewcelX" or the "Company") (Nasdaq: NCEL), a clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 ...
- 9mo agoNCELNewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering ConferencesPR NewswireNewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a clinical-stage cell therapy company advancing transformative treatments for chronic...
- 10mo agoNCELNewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune SuppressionPR NewswireNewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today...
- 10mo agoNCELNewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory BoardPR NewswireNewcelX Ltd. (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and...
- 11mo agoNCELNewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in ChinaPR NewswireNewcelX Ltd. (Nasdaq: NCEL), a next-generation biotechnology company developing advanced cell-therapy and neuroscience-driven therapeutics, today...
- 11mo agoNCELNewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological InstitutePR NewswireNewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies...
- 1y agoNCELNewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory BoardPR NewswireNewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for neurodegenerative and...
- 1y agoNCELNewcelX CEO Issues Letter to ShareholdersPR NewswireNewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for...
- 1y agoNCELNewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.PR NewswireNewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule...
- 1y agoNLSPNLSPWNCELNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of MergerPR NewswireNewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and...